<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614558</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT0761</org_study_id>
    <nct_id>NCT04614558</nct_id>
  </id_info>
  <brief_title>Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance</brief_title>
  <official_title>A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether Isatuximab can help improve kidney function of&#xD;
      participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for&#xD;
      the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to&#xD;
      treat MGRS. This means that the use of isatuximab in this study is considered&#xD;
      'investigational'.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monoclonal gammopathy is a common disorder but only a small fraction of patients with&#xD;
      monoclonal gammopathy of undetermined significance (MGUS) develop renal disease and the&#xD;
      reason for abnormal deposition of immunoglobulin in renal parenchyma remains unclear in these&#xD;
      disorders. The proposed research will be conducted as a part of clinical trial which intends&#xD;
      to prospectively evaluate the effect of anti-plasma cell therapy on renal outcomes in&#xD;
      patients with monoclonal gammopathy of renal significance (MGRS). The study specifically&#xD;
      intends to sequence the immunoglobulin heavy and light chain genes to determine any&#xD;
      abnormalities that could lead to production of a misfolded immunoglobulin thus leading to&#xD;
      deposition in renal parenchyma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study will be a single arm, prospective, multi-center, phase II, open- label study including 27 subjects in total. The study will consist of a screening phase, treatment phase, post-treatment observation phase and follow-up phase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Renal Response Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Renal response defined as a decrease in 24-hour proteinuria by &gt;50% at any point post therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The number of adverse events recorded for participants using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Immunoglobulin Gene Mutations</measure>
    <time_frame>Baseline, up to 4 weeks prior to treatment</time_frame>
    <description>The percentage of participants with immunoglobulin gene mutations as determined by next generation sequencing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Monoclonal Gammopathy</condition>
  <arm_group>
    <arm_group_label>Isatuximab for MGRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.&#xD;
Isatuximab (SAR) is monoclonal antibody (mAb).</description>
    <arm_group_label>Isatuximab for MGRS</arm_group_label>
    <other_name>Sarclisa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Renal biopsy proven diagnosis of an MGRS disorder including the following:&#xD;
&#xD;
               1. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)&#xD;
&#xD;
               2. C3 glomerulopathy associated with monoclonal gammopathy&#xD;
&#xD;
               3. Non-Amyloid Fibrillary Glomerulonephritis&#xD;
&#xD;
               4. Light chain Proximal Tubulopathy&#xD;
&#xD;
               5. Immunotactoid Glomerulopathy&#xD;
&#xD;
             A concurrent diagnosis of Monoclonal gammopathy (with +ve Serum and/or Urine protein&#xD;
             electrophoresis or Bone marrow biopsy) is required in patients with C3 glomerulopathy&#xD;
             but not for other disorders. Patients with concurrent MGUS, non-high risk smoldering&#xD;
             myeloma are eligible for enrollment.&#xD;
&#xD;
          2. Measurable Proteinuria ≥1gram over 24 hours.&#xD;
&#xD;
          3. Prior Therapy: Newly diagnosed as well as patients with previous therapy but&#xD;
             persistent renal dysfunction and persistent proteinuria ≥1gram over 24 hours are&#xD;
             eligible for enrollment. Patients who received a prior cluster of differentiation 38&#xD;
             (CD38) antibody therapy are not eligible for study. In patients who have received&#xD;
             prior therapy a wash out period of 12 weeks for chemotherapy based therapies and 24&#xD;
             weeks for Rituximab based therapies is required between completion of prior therapy&#xD;
             and cycle 1 Day1 of study therapy.&#xD;
&#xD;
          4. Age ≥18 years.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.&#xD;
&#xD;
          6. Life expectancy of greater than 6 months&#xD;
&#xD;
          7. Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
        Leukocytes ≥3,000/microliters (mcL)&#xD;
&#xD;
          1. absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
          2. platelets ≥100,000/mcL&#xD;
&#xD;
          3. total bilirubin within normal institutional limits&#xD;
&#xD;
          4. Aspartate aminotransferase (AST) (SGOT)/alanine transaminase (ALT)(SGPT) ≤2.5 ×&#xD;
             institutional upper limit of normal&#xD;
&#xD;
          5. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who have had chemotherapy based therapy within 12 weeks or Rituximab&#xD;
             based therapy within prior 24 weeks prior to starting the cycle 1 Day 1 of trial&#xD;
             therapy&#xD;
&#xD;
          2. Participants who are receiving any other investigational agents concurrently.&#xD;
&#xD;
          3. History of severe allergic reactions or anaphylaxis attributed to compounds of similar&#xD;
             chemical or biologic composition to Isatuximab.&#xD;
&#xD;
          4. Diagnosis of Multiple Myeloma or High risk smoldering Multiple Myeloma or a B cell&#xD;
             lymphoma meeting criteria for therapy.&#xD;
&#xD;
          5. Renal Biopsy showing the coexistence of other significant diagnosis e.g. diabetic&#xD;
             nephropathy.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          7. Pregnant and Lactating women are excluded from this study because there is an unknown&#xD;
             but potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with Isatuximab.&#xD;
&#xD;
          8. HIV-positive Participants are ineligible because of increased risk of lethal&#xD;
             infections when treated with immunosuppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Divaya Bhutani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Medicine at the Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Nurse Navigator</last_name>
    <phone>212-342-5162</phone>
    <email>cancerclinicaltrials@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Research Nurse Navigator</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Divaya Bhutani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan Hogan, MD</last_name>
      <phone>215-662-2638</phone>
      <email>Jonathan.Hogan2@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Hogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Divaya Bhutani</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

